Study of the efficacy of naltrexone on positive and negative symptoms in schizophrenic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110093010N4

Enrollment

Registered

2012-12-07

Start date

2012-03-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Placebo in cap form. 2 cap bid. Intervention 2: Naltrexone cap. 2 cap bid.

Placebo

Treatment - Drugs

Placebo in cap form. 2 cap bid

Naltrexone cap. 2 cap bid.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: all schizophrenic patients hospitalized in Farabi Hospital. Exclusion criteria: 1) Any patients who refuse to participate in the study. 2) Any sensitivity to naltrexone.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Positive and negative symptoms. Timepoint: Before the intervention and after 12 weeks. Method of measurement: PaNSS (Anderson test) scores.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Faezeh Tatari

Kermanshah University of Medical Sciences

ftatari@kums.ac.ir ; fztatari@yahoo.com+98 83 1836 3319

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026